Pneumococcal 13-valent conjugate vaccine for the prevention of invasive pneumococcal disease in children and adults
Pneumococcal 13-valent conjugate vaccine for the prevention of invasive pneumococcal disease in children and adults
Pneumococcal disease remains a global problem despite the availability of effective conjugate vaccines. The 13-valent pneumococcal conjugate vaccine (PCV13) extends the valency of PCV7 by including six additional serotypes highly associated with invasive pneumococcal disease (IPD). Comparisons between PCV13 and PCV7 or the pneumococcal polysaccharide vaccine have established noninferiority of PCV13 for both safety and immunogenicity profiles for use in children and adults, respectively. At the end of 2011, PCV13 had been approved and launched in 104 countries worldwide, with 54 including the vaccine in their pediatric national immunization program. Surveillance data from early adopters of PCV13 has indicated reductions are occurring in both overall IPD and IPD caused by the six non-PCV7 serotypes; early reports of serotype replacement in carriage are also emerging. While serotype replacement for PCV7 was observed to varying degrees for both carriage and disease, the extent to which this will occur for PCV13 is yet to be determined.
889-902
Gladstone, R.A.
c75d747c-0663-49e3-8d81-4e797eb79d0a
Jefferies, Johanna M.C.
9468e292-0b41-412d-9470-944e257c7bcf
Faust, S.
f97df780-9f9b-418e-b349-7adf63e150c1
Clarke, S.
f7d7f7a2-4b1f-4b36-883a-0f967e73fb17
August 2012
Gladstone, R.A.
c75d747c-0663-49e3-8d81-4e797eb79d0a
Jefferies, Johanna M.C.
9468e292-0b41-412d-9470-944e257c7bcf
Faust, S.
f97df780-9f9b-418e-b349-7adf63e150c1
Clarke, S.
f7d7f7a2-4b1f-4b36-883a-0f967e73fb17
Gladstone, R.A., Jefferies, Johanna M.C., Faust, S. and Clarke, S.
(2012)
Pneumococcal 13-valent conjugate vaccine for the prevention of invasive pneumococcal disease in children and adults.
Expert Review of Vaccines, 11 (8), .
(doi:10.1586/erv.12.68).
(PMID:23002969)
Abstract
Pneumococcal disease remains a global problem despite the availability of effective conjugate vaccines. The 13-valent pneumococcal conjugate vaccine (PCV13) extends the valency of PCV7 by including six additional serotypes highly associated with invasive pneumococcal disease (IPD). Comparisons between PCV13 and PCV7 or the pneumococcal polysaccharide vaccine have established noninferiority of PCV13 for both safety and immunogenicity profiles for use in children and adults, respectively. At the end of 2011, PCV13 had been approved and launched in 104 countries worldwide, with 54 including the vaccine in their pediatric national immunization program. Surveillance data from early adopters of PCV13 has indicated reductions are occurring in both overall IPD and IPD caused by the six non-PCV7 serotypes; early reports of serotype replacement in carriage are also emerging. While serotype replacement for PCV7 was observed to varying degrees for both carriage and disease, the extent to which this will occur for PCV13 is yet to be determined.
This record has no associated files available for download.
More information
Published date: August 2012
Organisations:
Faculty of Medicine
Identifiers
Local EPrints ID: 348144
URI: http://eprints.soton.ac.uk/id/eprint/348144
ISSN: 1476-0584
PURE UUID: 9bdbb207-1363-447d-b158-bd6cd0ed58b7
Catalogue record
Date deposited: 07 Feb 2013 12:59
Last modified: 15 Mar 2024 03:26
Export record
Altmetrics
Contributors
Author:
R.A. Gladstone
Author:
Johanna M.C. Jefferies
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
